

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 A61P17/02

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} & \mbox{A61P} \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, BIOSIS, EMBASE, PASCAL, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
P,A	WO 03/018758 A (KOMALAVILAS PADMINI; BROPHY COLLEEN (US); LOKESH JOSHI (US); PANITCH) 6 March 2003 (2003-03-06) claims 1-72	1-23		
P, A	TESSIER DERON J ET AL: "The small heat shock protein (HSP) 20 is dynamically associated with the actin cross-linking protein actinin."  THE JOURNAL OF SURGICAL RESEARCH. 1 MAY 2003, vol. 111, no. 1, 1 May 2003 (2003-05-01), pages 152-157, XP001182463 ISSN: 0022-4804 the whole document	1-23		

X Further documents are listed in the continuation of box C.	γ Patent family members are listed in annex.
Special categories of cited documents:      "A" document defining the general state of the art which is not considered to be of particular relevance     "E" earlier document but published on or after the international filling date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filling date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>
Date of the actual completion of the international search	Date of mailing of the international search report
14 July 2004	22/07/2004
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Fayos, C

3

0 (0	-V POOLIMENTS CONSIDERED TO BE DELEVANT	PC1/US2004/004999		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category Citation of document, with indication, where appropriate, of the relevant passages  Relevant to claim No.				
Category	Oracion of document, with indication, who is appropriate, or the research	Too van to stam ve		
P,A	PARMITER CATHERINE MARGARET ET AL: "Protein transduction of biomimetic peptides leads to changes in the actin cytoskeleton of 3T3 cells." FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03), pages Abstract No. 599.6 URL-http://ww, XP009033553 & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; SAN DIEGO, CA, USA; APRIL 11-15, 2003 ISSN: 0892-6638 abstract	1-23		
A	BROPHY C M ET AL: "The small heat shock-related protein-20 is an actin-associated protein."  JOURNAL OF VASCULAR SURGERY: OFFICIAL PUBLICATION, THE SOCIETY FOR VASCULAR SURGERY 'AND! INTERNATIONAL SOCIETY FOR CARDIOVASCULAR SURGERY, NORTH AMERICAN CHAPTER. FEB 1999, vol. 29, no. 2, February 1999 (1999-02), pages 326-333, XP009033572 ISSN: 0741-5214 the whole document	1-23		

3



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  Although claims 1-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Information or patent family members

intentional Application No PCT/US2004/004999

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 03018758 A	06-03-2003	CA WO US	2458574 A1 03018758 A2 2003060399 A1	06-03-2003 06-03-2003 27-03-2003

### **PATENT COOPERATION TREATY**

rom the				ļ	RECEIVED
TERNATIONAL SEAF	RCHING AUTHO	DRITY			_ 2 0 JUL 2004
To:				PC	WIPO PCT
					WIPO PCT
see form PCT/ISA/220			WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)		
			Date of mailing (day/month/year) see	e form PCT/ISA/2	10 (second sheet)
Applicant's or agent's file	reference		TOD FURTHER	ACTION	
see form PCT/ISA/22			FOR FURTHER ACTION See paragraph 2 below		
International application I		International filing date (20.02.2004	day/month/year)	Priority date (day/month/year) 21.02.2003	
International Patent Clas	sification (IPC) or	both national classification	and IPC		
A61K38/17, A61P17					
Applicant		,			
ARIZONA BOARD	OF REGENTS				
1. This opinion co	ontains indicati	ons relating to the fol	lowing items:		
·			J		
⊠ Box No. I	Basis of the op	oinion			
⊠ Box No. II	Priority	ment of opinion with reg	uard to povolty inventi	ve sten and ind	ustrial applicability
⊠ Box No. III			ald to noverty, invent	ve step and me	dottal applications
☐ Box No. IV 図 Box No. V	Lack of unity of Reasoned states applicability: c	tement under Rule 43 <i>bi</i> itations and explanation	is.1(a)(i) with regard to as supporting such sta	novelty, invent	tive step or industrial
☐ Box No. VI	Certain docum		1. 0		
☐ Box No. VII		s in the international ap	plication		
☐ Box No. VIII		vations on the internatio			
2. FURTHER ACT					
If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.					
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.					
For further option	ons, see Form P	CT/ISA/220.			
3. For further deta	ils, see notes to	Form PCT/ISA/220.			
ı					
Name and mailing addr	ess of the ISA:		Authorized Officer		stiches Petanian,

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Fayos, C

Telephone No. +49 89 2399-2180



### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/004999

	Вох	No	. I Basis of the opinion
1.	With the I	reg lang	pard to the <b>language</b> , this opinion has been established on the basis of the international application in uage in which it was field, unless otherwise indicated under this item.
		lang	s opinion has been established on the basis of a translation from the original language into the following guage , which is the language of a translation furnished for the purposes of international search der Rules 12.3 and 23.1(b)).
2.	With nece	reg essa	gard to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application and ary to the claimed invention, this opinion has been established on the basis of:
	a. ty	/pe d	of material:
	D	⊴	a sequence listing
		]	table(s) related to the sequence listing
	b. fo	orma	at of material:
	, 1	⅓	in written format
		Ø	in computer readable form
	c. ti	me (	of filing/furnishing:
	E		contained in the international application as filed.
			filed together with the international application in computer readable form.
	Ď	$\boxtimes$	furnished subsequently to this Authority for the purposes of search.
3.		ha	addition, in the case that more than one version or copy of a sequence listing and/or table relating theretos been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.
4.	Ado	ditio	nal comments:

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/004999

Во	x No. II	Priority			
1. 🛛	The fol	lowing document has not been furnished:			
	$\boxtimes$	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).			
		translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).			
	Conse neverti	quently it has not been possible to consider the validity of the priority claim. This opinion has neless been established on the assumption that the relevant date is the claimed priority date.			
2. 🗆	has be	pinion has been established as if no priority had been claimed due to the fact that the priority claim en found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international ate indicated above is considered to be the relevant date.			
3. Ac	3. Additional observations, if necessary:				

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/004999

	No. III Non-establishment of licability	opir	nion with regard to novelty, inventive step and industrial		
The obvi	questions whether the claimed in ious), or to be industrially applica	nvent ble h	ion appears to be novel, to involve an inventive step (to be non ave not been examined in respect of:		
	the entire international application,				
	claims Nos. 1-23 (industrial applicability)				
bec	ause:				
	the said international application following subject matter which d	ı, or t loes ı	the said claims Nos. 1-23 (industrial applicability) relate to the not require an international preliminary examination (specify):		
	see separate sheet				
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
$\boxtimes$	no international search report has been established for the whole application or for said claims Nos.				
	and the standard provided for in Annex				
	the written form		has not been furnished		
			does not comply with the standard		
	the computer readable form		has not been furnished		
	·		does not comply with the standard		
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.				
	See separate sheet for further	detai	ls		

### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/004999

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-23

No: Claims

Inventive step (IS)

Yes: Claims

1-23

Claims

Industrial applicability (IA)

Yes: Claims

No: Claims 1-23 see separate sheet

2. Citations and explanations

see separate sheet

#### Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1- Claims 1-23 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 2- Reference is made to the following documents:
- D1: WO 03/018758 A (KOMALAVILAS PADMINI; BROPHY COLLEEN (US); LOKESH JOSHI (US); PANITCH) 6 March 2003 (2003-03-06)
- D2: TESSIER DERON J ET AL: "The small heat shock protein (HSP) 20 is dynamically associated with the actin cross-linking protein actinin." THE JOURNAL OF SURGICAL RESEARCH. 1 MAY 2003, vol. 111, no. 1, 1 May 2003 (2003-05-01), pages 152-157, XP001182463 ISSN: 0022-4804
- D3: PARMITER CATHERINE MARGARET ET AL: "Protein transduction of biomimetic peptides leads to changes in the actin cytoskeleton of 3T3 cells." FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03), pages Abstract No. 599.6 URL-http://ww, XP009033553 & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; SAN DIEGO, CA, USA; APRIL 11-15, 2003 ISSN: 0892-6638
- D4: BROPHY C M ET AL: "The small heat shock-related protein-20 is an actin-associated protein." JOURNAL OF VASCULAR SURGERY: OFFICIAL PUBLICATION, THE SOCIETY FOR VASCULAR SURGERY [AND] INTERNATIONAL SOCIETY FOR CARDIOVASCULAR SURGERY, NORTH AMERICAN CHAPTER. FEB 1999, vol. 29, no. 2, February 1999 (1999-02), pages 326-333, XP009033572 ISSN: 0741-5214

### NOVELTY - Art. 33 (1) and (2) PCT and INVENTIVE STEP - Art. 33 (1) and (3) PCT

None of the prior art documents cited in the search report explicitly mentions or appears to suggest the use of HSP20 or derivatives thereof (see present claims 1 and 13) for the manufacture of a medicament for reducing scar formation or for

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

PCT/US2004/004999

promoting wound healing.

Claims 1-23 seem appear therefore to be novel and inventive over the prior art at hand.

### INDUSTRIAL APPLICABILITY - Art. 33 (1) and (4) PCT

4- For the assessment of the present claims 1-23 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.